Trial · NCT00979862
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
NCT00979862, Phase 1, Completed, National Cancer Institute (NCI)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma. Trials, record NCT00979862. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00979862
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
- NCT number
- NCT00979862
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 47 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm
- Interventions
- Cediranib Maleate, Cilengitide, Laboratory Biomarker Analysis
- First posted
- 2009-09-18
- Last updated
- 2015-04-15
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety profile of cediranib maleate based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 | 28 days | The proportion of patients with serious or life threatening toxicities will be estimated along with 95% confidence intervals. |
| Secondary | Change in markers | From baseline to up to 7 days after completion of treatment | Summarized using descriptive statistics. Statistical graphics such as box plots will be used to present the summary statistics at each time point. The differences before and during treatment will be tested using paired statistics. |
| Secondary | Overall survival (OS) | Time from the date of treatment start to the date of death, assessed up to 6 months | Median time of survival along with 95% confidence interval will be estimated using Kaplan-Meier method. |
| Secondary | Progression-free survival | At 6 months | The probability of 6-month progression-free survival will be estimated using binomial distribution. |
| Secondary | Radiographic responses using MRI scan | Up to 6 months | The probability of the responses will be estimated using binomial distribution. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01CA137443 | Adult Brain Tumor Consortium (ABTC) | GROSSMAN, STUART A; PRADOS, MICHAEL D | JOHNS HOPKINS UNIVERSITY | NATIONAL CANCER INSTITUTE | 2009 to 2013 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00979862
GET https://conductscience.org/api/trials/v1/NCT00979862/registered